Q-omics provides the consensus-scored VANGL2 profile across patient tissues and cancer cell-line models. VANGL2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VANGL2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, VANGL2 RNA expression shows 19,664 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, KICH, and KIRP as cancer lineages where VANGL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VANGL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VANGL2 survival associations across molecular data types. VANGL2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VANGL2 RNA expression–survival associations across cancer types. High VANGL2 expression shows unfavorable associations in ACC, LUAD and SKCM, but favorable associations in LUSC, UCS and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for VANGL2 RNA expression.
This table summarizes VANGL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for VANGL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VANGL2 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LUSC, UCEC and CHOL. The KICH box plot shows higher VANGL2 RNA expression in normal versus tumor tissue (log2 FC = −2.972, t-test p < 0.001).
This table shows molecular features associated with VANGL2 in patient tissues and cancer cell lines. In patient samples, VANGL2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, VANGL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
